Prophylactic HIV Drugs Market Size (2024 - 2029)

The prophylactic HIV drug market is experiencing stable growth, driven by the high global prevalence of HIV and the increasing demand for preventive medications. The market's expansion is supported by investments from non-profit organizations and pharmaceutical companies in HIV clinical research, as well as product launches and regulatory approvals. The COVID-19 pandemic has also influenced the market, as antiretroviral drugs used for HIV treatment were repurposed for COVID-19, impacting market dynamics. Despite these positive trends, challenges such as lower penetration in underdeveloped markets and potential side effects of the drugs may hinder growth.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Immune System Drugs Research Immunodeficiencies Research Prophylactic HIV Drugs Market Market Size

Market Size of Prophylactic HIV Drugs Industry

Prophylactic HIV Drugs Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR (2024 - 2029) 4.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Low

Major Players

Prophylactic HIV Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Prophylactic HIV Drugs Market Analysis

The Prophylactic HIV Drugs Market is expected to register a CAGR of 4.10% during the forecast period.

The market is expected to grow owing to factors such as the high prevalence of HIV cases, increasing government initiatives, and increasing research and development activities. In addition, growing awareness of HIV prevention is also expected to drive the market growth over the forecast period. The high burden of new and existing HIV cases is expected to boost the market growth over the study period.

For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) factsheet 2023, in 2022, 51 thousand new HIV infections were reported compared to 48 thousand new cases in previous years. Similarly, as per the same source, the number of people living with HIV in Brazil was reported to be 990 thousand in 2022. This shows the significantly high burden of HIV, which is expected to increase the need for prophylactic HIV drugs to prevent spread and is likely to propel the market growth over the forecast period.

A large number of non-profit and government organizations are initiating various programs or studies to prevent HIV through various products, which is likely to propel the growth of the market. For instance, in April 2024, the CATALYST study of the United States Agency for International Development (USAID) expanded HIV prevention options for women and girls in Africa. This study provides complete information on and access to three biomedical HIV prevention methods, which include daily oral pre-exposure prophylaxis (PrEP) and newly-introduced injectable cabotegravir for PrEP (CAB PrEP) and others. Hence, government initiatives to provide awareness on the prevention of HIV are expected to drive market growth over the study period.

In addition, product developments, launches, and approval by regulatory authorities are expected to support market expansion over the forecast period. For instance, in October 2023, Gilead Sciences Inc. reported the phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe. The study assesses the persistence of lenacapavir compared with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in people who benefit from pre-exposure prophylaxis (PrEP). Thus, such efforts by market participants may result in the launch of advanced preventive therapy, which is expected to boost market growth over the forecast period.

However, lower penetration in an underdeveloped market and side effects of this drug, such as vomiting, nausea, tiredness, and diarrhea, are expected to restrain the market's growth over the forecast period.

Prophylactic HIV Drugs Industry Segmentation

As per the scope of the report, human immunodeficiency virus (HIV) is a chronic and life-threatening disease. The disease can be transferred from one person to another through blood-to-blood or sexual contact. HIV prophylactic drugs are the medication that is given to prevent HIV disease before it even occurs. 

The prophylactic HIV drugs market is segmented by drug, dosage form, and geography. By drug, the market is segmented into tenofovir, emtricitabine, and other drugs. The other drugs category includes cabotegravir, lenacapavir, and others. By dosage form, the market is segmented into oral and topical. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market sizes and forecasts in terms of value (USD) for the above segments.

By Drug
Tenofovir
Emtricitabine
Other Drugs
By Dosage Form
Oral
Topical
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Prophylactic HIV Drugs Market Size Summary

The prophylactic HIV drug market is poised for steady growth, driven by the high global prevalence of HIV and the increasing demand for preventive medications. The market has shown resilience despite the disruptions caused by the COVID-19 pandemic, which saw some antiretroviral drugs being repurposed for COVID-19 treatment. This shift, while initially impacting the market, has led to a resurgence in diagnostic and manufacturing activities, supporting market stability. The involvement of non-profit organizations and significant investments from pharmaceutical and biotechnology companies in HIV research are further propelling market expansion. Regulatory approvals and product launches, such as Excision's EBT-101, are expected to introduce advanced preventive therapies, enhancing market growth prospects. However, challenges such as lower penetration in underdeveloped markets and potential side effects of the drugs may pose constraints.

The oral drug segment is anticipated to dominate the market, attributed to its pharmacokinetic advantages and high patient compliance. The development of new oral drugs and a robust pipeline of candidates are key factors driving this segment's growth. North America stands out as a significant revenue contributor, supported by a technologically advanced healthcare system and favorable reimbursement policies. The region's market growth is further bolstered by increased government funding for HIV prevention and treatment. The market is characterized by fragmentation, with numerous players like AbbVie, Gilead Sciences, and Merck & Co. Inc. actively participating. Recent FDA approvals, such as Sunlenca and Cabenuva, highlight ongoing advancements in HIV treatment options, reinforcing the market's growth trajectory.

Explore More

Prophylactic HIV Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 High Prevalence of HIV/AIDS

      2. 1.2.2 Increasing Government Initiatives

      3. 1.2.3 Increasing R&D Activities

    3. 1.3 Market Restraints

      1. 1.3.1 Lower Penetration in Underdeveloped Markets

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Drug

      1. 2.1.1 Tenofovir

      2. 2.1.2 Emtricitabine

      3. 2.1.3 Other Drugs

    2. 2.2 By Dosage Form

      1. 2.2.1 Oral

      2. 2.2.2 Topical

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Prophylactic HIV Drugs Market Size FAQs

The Prophylactic HIV Drugs Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)

Merck & Co., Inc., Cipla Inc, Bristol-Myers Squibb Company, Viatris Inc. (Mylan) and Johnson & Johnson are the major companies operating in the Prophylactic HIV Drugs Market.

Prophylactic HIV Drugs Market Report Snapshots

Prophylactic HIV Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)